Focus on developing specialty business will prop up growth

Despite the key US market continuing to be a major pain point, recovery in India business, improvement in Taro’s (US subsidiary) sales and traction in emerging market sales promise better times for Sun Pharma. However, the stock of Sun Pharma fell 4 per cent on Wednesday tracking the fall in its second quarter earnings. The company has reported a drop of around 59 per cent in consolidated net...